Patents by Inventor Irina Apostolou

Irina Apostolou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDCP1-TARGETED THERAPIES
    Publication number: 20220119545
    Abstract: The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.
    Type: Application
    Filed: November 7, 2019
    Publication date: April 21, 2022
    Inventors: Lewis C. CANTLEY, Stephen P. SOLTOFF, Brooke M. EMERLING, George POULOGIANNIS, Cindy M. HODAKOSKI, Hui LIU, Irina APOSTOLOU, Brian Gaither BATES, Kimberly Ann MARQUETTE, Eric M. BENNETT, Lidia MOSYAK, Lioudmila G. TCHISTIAKOVA, Edward Christian ROSFJORD, Isaac J. RONDON, Chao Bai HUANG
  • Anti-ILT5 antibodies and ILT5-binding antibody fragments
    Patent number: 9828425
    Abstract: Disclosed herein are antibodies and ILT5-binding fragments thereof that specifically bind to ILT5, e.g., human ILT5 (hILT5), and pharmaceutical compositions comprising such ILT5-binding antibodies and ILT5-binding fragments thereof.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: November 28, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig
  • IMMUNOREGULATION BY ANTI-ILTS ANTIBODIES AND ILTS-BINDING ANTIBODY FRAGMENTS
    Publication number: 20170158765
    Abstract: Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to induce an immunostimulatory effect in a T cell when such a T cell is contacted with an antigen presenting cell (APC) that has been previously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to inhibit a response in a T cell (e.g., a proliferative response) when such a T cell is concomitantly contacted, or has previously been contacted, with an APC, which APC is simultaneously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.
    Type: Application
    Filed: December 7, 2016
    Publication date: June 8, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig, Lou Vaickus
  • Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
    Patent number: 9534051
    Abstract: Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: January 3, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig, Lou Vaickus
  • ANTI-ILT5 ANTIBODIES AND ILT5-BINDING ANTIBODY FRAGMENTS
    Publication number: 20150197570
    Abstract: Disclosed herein are antibodies and ILT5-binding fragments thereof that specifically bind to ILT5, e.g., human ILT5 (hILT5), and pharmaceutical compositions comprising such ILT5-binding antibodies and ILT5-binding fragments thereof.
    Type: Application
    Filed: March 11, 2015
    Publication date: July 16, 2015
    Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig
  • Anti-ILT5 antibodies and ILT5-binding antibody fragments
    Patent number: 9023997
    Abstract: Disclosed herein are antibodies and ILT5-binding fragments thereof that specifically bind to ILT5, e.g., human ILT5 (hILT5), and pharmaceutical compositions comprising such ILT5-binding antibodies and ILT5-binding fragments thereof.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: May 5, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig
  • IMMUNOREGULATION BY ANTI-ILT5 ANTIBODIES AND ILT5-BINDING ANTIBODY FRAGMENTS
    Publication number: 20150010564
    Abstract: Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.
    Type: Application
    Filed: August 19, 2014
    Publication date: January 8, 2015
    Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig, Lou Vaickus
  • Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments
    Patent number: 8846397
    Abstract: Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to induce an immunostimulatory effect in a T cell when such a T cell is contacted with an antigen presenting cell (APC) that has been previously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to inhibit a response in a T cell (e.g., a pro-liferative response) when such a T cell is concomitantly contacted, or has previously been contacted, with an APC, which APC is simultaneously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: September 30, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig, Lou Vaickus
  • IMMUNOREGULATION BY ANTI-ILT5 ANTIBODIES AND ILT5-BINDING ANTIBODY FRAGMENTS
    Publication number: 20130052196
    Abstract: Disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to induce an immunostimulatory effect in a T cell when such a T cell is contacted with an antigen presenting cell (APC) that has been previously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof to inhibit a response in a T cell (e.g., a pro-liferative response) when such a T cell is concomitantly contacted, or has previously been contacted, with an APC, which APC is simultaneously contacted with the anti-ILT5 antibody or ILT5-binding fragment. Also disclosed herein are methods of using anti-ILT5 antibodies and ILT5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.
    Type: Application
    Filed: January 20, 2011
    Publication date: February 28, 2013
    Applicant: TOLERX, INC.
    Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig, Lou Vaickus
  • ANTI-ILT5 ANTIBODIES AND ILT5-BINDING ANTIBODY FRAGMENTS
    Publication number: 20130030156
    Abstract: Disclosed herein are antibodies and ILT5-binding fragments thereof that specifically bind to ILT5, e.g., human ILT5 (hILT5), and pharmaceutical compositions comprising such ILT5-binding antibodies and ILT5-binding fragments thereof.
    Type: Application
    Filed: January 20, 2011
    Publication date: January 31, 2013
    Applicant: TOLERX, INC.
    Inventors: Irina Apostolou, Paul Ponath, Joe Ponte, Michael Rosenzweig
  • Pharmaceutical composition comprising PIM-activated NKT cells, and use thereof in therapy
    Publication number: 20060263376
    Abstract: The invention concerns a pharmaceutical composition comprising at least a PIM-activated NKT cell and the use of at least one PIM and/or a PIM-activated NKT cell for treating a disease for which a granulomatous type of immune response is desired.
    Type: Application
    Filed: April 11, 2006
    Publication date: November 23, 2006
    Inventors: Irina Apostolou, Gabriel Gachelin, Philippe Kourilsky, Yousuke Takahama